RPG Life Sciences Limited
Momentum (85/100) does the heavy lifting; valuation (33/100) is the drag.
Fair valueRPG Life Sciences Limited earns a Hold from StocksWizard, with a blended score of 55/100. We put fair value near ₹2,360.67; at ₹2,768.2 that leaves roughly 15% downside, so the stock screens overvalued by 15%. On 42.2x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 8% below its 52-week high of ₹3,017.1 and 60% above the low of ₹1,726.93. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 8 of 13 investability checks, with durability 71, valuation 40 and momentum 85 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,888.54.
1-year price
EOD · 2026-07-3152-week range
-8.25% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold55Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 20.3%
- Pass: Low debt (D/E < 0.5): 0.03x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 24%
- Fail: Earnings growing: -75%
- Pass: Net margin ≥ 10%: 16.3%
- Pass: Current ratio > 1.5: 3.48
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 17.09
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter75.3%
- Institutions5.6%
- Public & other19.1%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (20.3%).
- Lightly leveraged balance sheet.
- Healthy profit margin (16.3%).
- Financially solid — Altman Z 17.09.
Opportunities
- Revenue growing (24% YoY).
Bear case
Threats
- Earnings contracting year on year.
About RPG Life Sciences Limited
RPG Life Sciences develops, manufactures, and markets branded formulations, generic drugs, and synthetic active pharmaceutical ingredients across multiple therapeutic categories including immunosuppressants, anti-psychotics, anti-anginals, anthelmintics, and anti-convulsants. Operating in India and internationally, the company supplies both generic immunosuppressant therapies and finished dosage forms.
RPG Life Sciences Limited — frequently asked questions
Is RPG Life Sciences Limited a buy, hold or sell?
StocksWizard currently rates RPG Life Sciences Limited (RPGLIFE) a Hold, based on a blended score of 55/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is RPG Life Sciences Limited's fair value?
Our blended DCF and relative-valuation model estimates RPG Life Sciences Limited's fair value at about ₹2,360.67, versus a current price of ₹2,768.2 — roughly 15% downside. On that basis the stock looks overvalued by 15%.
Is RPG Life Sciences Limited financially healthy?
RPG Life Sciences Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has RPG Life Sciences Limited's share price performed?
RPG Life Sciences Limited is up 20% over three months, and last traded at ₹2,768.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.